167
Participants
Start Date
September 19, 2017
Primary Completion Date
March 14, 2024
Study Completion Date
March 14, 2024
CAN04
A fully humanized monoclonal immunoglobulin G1 (IgG1) antibody (hmAb) in aqueous solution administered by i.v. infusion.
Cisplatin
Standard of care treatment
Gemcitabine
Standard of care treatment
Nab-paclitaxel
Standard of care treatment
Carboplatin
Standard of care treatment
Pemetrexed
Standard of care treatment
Institut Jules Bordet, Brussels
Pauls Stradiņš Clinical University Hospital, Riga
Riga East Clinical University Hospital, Riga
Rigshospitalet, Department of Oncology, Copenhagen
Herlev og Gentofte Hospital, Herlev
University Hospital Gasthuisberg, Leuven
Odense University Hospital, Odense
Landeskrankenhaus Salzburg, Salzburg
Aalborg University Hospital, Aalborg
Charité Universitätsmedizin Berlin, Berlin
East Tallinn Central Hospital, Tallinn
Hospital 12 de Octubre, Madrid
Hospital Universitario Quirónsalud Madrid, Madrid
Hospital Universitario Central de Asturias, Oviedo
The Hospital of Lithuanian University of Health Sciences, Kaunas
Tartu University Hospital, Tartu
Universitätsklinikum Ulm, Ulm
Medizinische Universität Wien, Vienna
CHU de Liège, Liège
Asklepios Klinik Altona, Hamburg
National Cancer Institute, Vilnius
Netherlands Cancer Institute, Amsterdam
Erasmus University Medical Center, Department of Medical Oncology, Rotterdam
Oslo University Hospital, Radiumhospitalet, Oslo
Karolinska University Hospital, Stockholm
Lead Sponsor
Cantargia AB
INDUSTRY